
THIS CIRCULAR IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

If you are in any doubt as to any aspect of this circular, or as to the action to be taken, you should consult your stockbroker or other licensed securities dealer, bank manager, solicitor, professional accountant or other professional advisers.

If you have sold or transferred all your shares in Alebund Pharmaceuticals (Jiangsu) Limited, you should at once hand this circular, together with the form of proxy, to the purchaser or transferee or to the bank, stockbroker or other agent through whom the sale or transfer was effected for transmission to the purchaser or transferee.

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this circular, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this circular.



Alebund Pharmaceuticals (Jiangsu) Limited 禮邦醫藥(江蘇)股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 09637)

- (1) PROPOSED APPOINTMENT OF AUDITOR
- (2) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES
- (3) PROPOSED GRANTING OF GENERAL MANDATE TO
REPURCHASE H SHARES AND
- (4) NOTICE OF THE EXTRAORDINARY GENERAL MEETING

All capitalised terms used in this circular have the meanings set out in the section headed "Definitions" in this circular. A letter from the Board is set out on pages 4 to 9 of this circular.

The Company will convene the EGM at 10:00 a.m. on Friday, August 14, 2026 at Meeting Room 303, 1206, Hong Kong Plaza South Building, No. 283, Middle Huaihai Road, Huangpu District, Shanghai, PRC, notice of which is set out on pages EGM-1 to EGM-5 of this circular. The proxy form for use at the EGM is enclosed with this circular and has also been published on the website of the Stock Exchange (www.hkexnews.hk) and the website of the Company (www.alebund.com).

If you intend to appoint a proxy to attend the EGM, you are requested to complete and return the form of proxy in accordance with the instructions printed thereon as soon as possible and in any event not less than 24 hours before the time appointed for holding the EGM or any adjournment thereof. The proxy form must be signed by you or your attorney duly authorised in writing or, in case of a legal person, must either be executed under its seal or under the hand of its director or other attorney duly authorised to sign the same. If the proxy form is signed by an attorney of the appointor, the power of attorney authorising that attorney to sign, or other document of authority, must be notarized. Completion and return of the form of proxy will not preclude you from attending and voting in person at the EGM or any adjournment thereof should you so wish.

July 24, 2026

CONTENTS

	<i>Page</i>
DEFINITIONS	1
LETTER FROM THE BOARD	4
APPENDIX I – EXPLANATORY STATEMENT ON THE REPURCHASE MANDATE	I-1
NOTICE OF EXTRAORDINARY GENERAL MEETING	EGM-1

DEFINITIONS

In this circular, unless otherwise defined or the context otherwise requires, the following expressions have the following meanings:

“Articles of Association”	the articles of association of the Company as amended, modified or otherwise supplemented from time to time
“associate(s)”	has the meaning ascribed under the Listing Rules
“Audit Committee”	the audit committee of the Company
“Board”	the board of Directors
“CCASS”	the Central Clearing and Settlement System established and operated by HKSCC
“Chairman”	the chairman of the Board
“China” or “PRC”	the People’s Republic of China, excluding, for the purposes of this circular only, Hong Kong, Macau Special Administrative Region of the People’s Republic of China and Taiwan
“Company” or “our Company”	Alebund Pharmaceuticals (Jiangsu) Limited (禮邦醫藥(江蘇)股份有限公司), a limited liability company established in the PRC on May 20, 2021 and converted into a joint stock company with limited liability on October 10, 2025
“connected person(s)”	has the meaning ascribed thereto under the Listing Rules
“Director(s)”	the director(s) of the Company
“EGM” or “Extraordinary General Meeting”	the extraordinary general meeting of the Company to be held at 10:00 a.m. on Friday, August 14, 2026 at Meeting Room 303, 1206, Hong Kong Plaza South Building, No.283, Middle Huaihai Road, Huangpu District, Shanghai, PRC or any adjournment thereof
“Group”	the Company and its subsidiaries
“H Share(s)”	overseas listed foreign shares issued by the Company with a nominal value of RMB1.00 each, which are listed on the Main Board of the Stock Exchange

DEFINITIONS

“HK\$”	Hong Kong dollars, the lawful currency of Hong Kong
“Hong Kong”	the Hong Kong Special Administrative Region of the PRC
“Issue Mandate”	a general mandate proposed to be granted to the Board to exercise all powers of the Company to allot, issue and/or deal with Shares (including any sale or transfer of Treasury Shares, if any) not exceeding 20% of the total issued Shares (excluding Treasury Shares) as at the date of passing the relevant special resolution at the EGM
“Latest Practicable Date”	July 22, 2026, being the latest practicable date prior to the publication of this circular for ascertaining certain information contained in this circular
“Listing Rules”	the Rules Governing the Listing of Securities on the Stock Exchange as amended, modified or otherwise supplemented from time to time
“Over-allotment Option”	the over-allotment option granted by the Company in connection with the Global Offering which was fully exercised on July 24, 2026 in respect of an aggregate of 8,513,300 H Shares
“Repurchase Mandate”	a general mandate proposed to be granted to the Board to exercise all powers of the Company to repurchase H Shares not exceeding 10% of the number of H Shares in issue (excluding treasury shares) as at the date of passing the relevant special resolution at the EGM
“RMB”	Renminbi Yuan, the lawful currency of the PRC
“Share(s)”	the Unlisted Share(s) and the H Share(s)
“Shareholder(s)”	holder(s) of the Share(s)
“Stock Exchange”	the Stock Exchange of Hong Kong Limited
“Takeovers Code”	codes on Takeovers and Mergers and Share Buy-backs issued by the Securities and Futures Commission of Hong Kong, as amended, modified or otherwise supplemented from time to time

DEFINITIONS

“Treasury Shares”	has the meaning ascribed to it under the Listing Rules
“Unlisted Share(s)”	domestic unlisted share(s) issued by the Company with a nominal value of RMB1.00 each
“%”	per cent

LETTER FROM THE BOARD



Alebund Pharmaceuticals (Jiangsu) Limited **禮邦醫藥(江蘇)股份有限公司**

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 09637)

Executive Directors:

Dr. Gavin Guoyao Xia (*Chairman of the Board and Chief Executive Officer*)
Jin Tian, M.D.
Ms. Wang Yun (汪昀)
Dr. Zhang Huading (張華丁)

Non-executive Director:

Dr. Lu An (魯安)

Independent non-executive Directors:

Dr. Xu Runhong (徐潤紅)
Dr. Zhui Chen
Mr. Leung Chi Wai (梁智維)

Registered Office, Headquarter and Principal Place of Business in the PRC:
Building 7
No. 7 Jinzhuang Road
Gaoxin District, Hanjiang District
Yangzhou City
Jiangsu Province
PRC

Principal Place of Business in Hong Kong:
46/F, Hopewell Centre
183 Queen's Road East
Wan Chai
Hong Kong

Hong Kong July 24, 2026

To the Shareholders

Dear Sir or Madam,

- (1) PROPOSED APPOINTMENT OF AUDITOR**
- (2) PROPOSED GRANTING OF GENERAL MANDATE TO ISSUE SHARES**
- (3) PROPOSED GRANTING OF GENERAL MANDATE TO REPURCHASE H SHARES AND**
- (4) NOTICE OF THE EXTRAORDINARY GENERAL MEETING**

I. INTRODUCTION

The purpose of this circular is to give you notice of the EGM and to provide you with information reasonably necessary to enable you to make an informed decision on whether to vote for or against the resolutions to be proposed at the EGM in respect of: (i) the proposed appointment of auditor; (ii) the proposed granting of the Issue Mandate; and (iii) the proposed granting of the Repurchase Mandate.

LETTER FROM THE BOARD

II. DETAILS OF THE RESOLUTIONS

The following resolutions will be proposed at the EGM for the Shareholders' consideration and, if thought fit, approval:

- (a) as an ordinary resolution: the proposed appointment of Ernst & Young as the auditor of the Company and the authorisation to the Board to fix its remuneration; and
- (b) as special resolutions: the proposed granting of the Issue Mandate, and the proposed granting of the Repurchase Mandate.

1. Proposed Appointment of Auditor

Upon the recommendation of the Audit Committee, such resolution was considered and approved by the Board on July 22, 2026. The Board proposes to pass an ordinary resolution for the appointment of Ernst & Young, the existing auditor of the Company, as the auditor of the Company effective until the conclusion of the next annual general meeting of the Company subject to the approval of the Shareholders at the EGM. The Board also proposes and recommends to the Shareholders to authorize the Board at the EGM to fix the remuneration of Ernst & Young as the auditor of the Company.

The estimated remuneration of Ernst & Young for the year ending December 31, 2026, as discussed with Ernst & Young and determined based on the Group's business scale and complexity, expected audit and review scope, timeline, required resources and professional expertise, is in the range of RMB2,000,000 to RMB2,200,000, subject to finalisation of the engagement terms and actual scope of work.

2. Proposed Granting of General Mandate to Issue Shares

In order to provide the Company with flexibility to issue Shares and/or sell or transfer Treasury Shares in a timely manner when appropriate, a special resolution will be proposed at the EGM to grant to the Board a general and unconditional mandate to allot, issue and/or deal with additional Shares and/or sell or transfer Treasury Shares of the Company, if any, not exceeding 20% of the total number of Shares in issue (excluding Treasury Shares, if any) as at the date of passing the relevant resolution at the EGM, as well as to authorise the Board to make corresponding amendments to the Articles of Association so as to reflect the increase in registered capital and changes to the shareholding structure of the Company upon any allotment and issuance of Shares under the above general mandate. The resolution was considered and approved by the Board on July 22, 2026.

As at the Latest Practicable Date, the total number of issued Shares was 339,852,231, comprising 227,122,189 H Shares and 112,730,042 Unlisted Shares, and the Company did not hold any Treasury Shares. Pursuant to the announcement on the full exercise of the Over-allotment Option dated July 24, 2026, the Over-allotment Option has been fully exercised and an aggregate of additional 8,513,300 H Shares will be issued and listed on the Stock

LETTER FROM THE BOARD

Exchange on July 29, 2026. The total number of issued Shares following the exercise of the Over-allotment Option will then be 348,365,531, comprising 235,635,489 H Shares and 112,730,042 Unlisted Shares. Subject to the passing of the relevant resolution and assuming that no further Shares (other than any H Shares allotted and issued pursuant to the exercise of the Over-allotment Option) are issued or repurchased and no Treasury Shares are held before the EGM, the Company would be allowed to allot, issue and/or deal with up to 69,673,106 Shares, either separately or concurrently, under the Issue Mandate. The maximum number of Shares which may be allotted, issued and/or dealt with under the Issue Mandate will be calculated based on the total number of Shares in issue (taking into account the exercise of Over-allotment Option but excluding Treasury Shares, if any) as at the date of passing of the relevant resolution at the EGM.

The Issue Mandate, if granted, will remain in force until the earliest of: (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required to be held under the Articles of Association or applicable laws and regulations; or (iii) the date on which the authority granted under the relevant resolution is revoked or varied by a special resolution of the Shareholders in general meeting.

The Directors confirm that, as at the Latest Practicable Date, the Company had no immediate plan to allot, issue and/or deal with additional Shares or sell or transfer Treasury Shares pursuant to the Issue Mandate. Any future issue of new H Shares under the Issue Mandate will be subject to applicable requirements under the Listing Rules, including application to the Stock Exchange for listing approval where required, and applicable PRC laws and regulatory requirements.

3. Proposed Granting of General Mandate to Repurchase H Shares

In order to provide the Company with flexibility to repurchase H Shares if and when appropriate, a special resolution will be proposed at the EGM to grant to the Board the Repurchase Mandate to repurchase H Shares on the Stock Exchange not exceeding 10% of the total number of H Shares in issue (excluding Treasury Shares, if any) as at the date of passing the relevant resolution at the EGM. The resolution was considered and approved by the Board on July 22, 2026.

As at the Latest Practicable Date, there were 227,122,189 H Shares in issue and the Company did not hold any Treasury Shares. Pursuant to the announcement on the full exercise of the Over-allotment Option dated July 24, 2026, the Over-allotment Option has been fully exercised and an aggregate of additional 8,513,300 H Shares will be issued and listed on the Stock Exchange on July 29, 2026. The total number of issued Shares following the exercise of the Over-allotment Option will then be 348,365,531, comprising 235,635,489 H Shares and 112,730,042 Unlisted Shares. Subject to the passing of the relevant resolution and assuming that no further H Shares (other than any H Shares allotted and issued pursuant to the exercise of the Over-allotment Option) are issued or repurchased and no Treasury Shares are held before the EGM, the Company would be allowed to repurchase up to 23,563,548 H Shares under the

LETTER FROM THE BOARD

Repurchase Mandate. The maximum number of H Shares which may be repurchased under the Repurchase Mandate will be calculated based on the total number of H Shares in issue (taking into account the exercise of Over-allotment Option but excluding Treasury Shares, if any) as at the date of passing of the relevant resolution at the EGM.

The Repurchase Mandate, if granted, will remain in force until the earliest of: (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required to be held under the Articles of Association or applicable laws and regulations; or (iii) the date on which the authority granted under the relevant resolution is revoked or varied by a special resolution of the Shareholders in general meeting.

If the Company repurchases any H Shares pursuant to the Repurchase Mandate, the Company may, subject to market conditions, capital management needs, the Listing Rules and applicable PRC laws and regulations, cancel the repurchased H Shares and reduce the registered capital of the Company, and/or hold the repurchased H Shares as Treasury Shares. If any repurchased H Shares are held as Treasury Shares, the Company will ensure that such Treasury Shares are appropriately identified and segregated, and the voting rights attached to Treasury Shares, if any, will be suspended in accordance with the Listing Rules and applicable laws and regulations.

An explanatory statement required by the Listing Rules to provide the Shareholders with information reasonably necessary to enable them to make an informed decision on whether to vote for or against the resolution approving the Repurchase Mandate is set out in Appendix I to this circular.

III. THE EGM

The EGM will be held at 10:00 a.m. (Hong Kong time) on Friday, August 14, 2026 at Meeting Room 303, 1206, Hong Kong Plaza South Building, No.283, Middle Huaihai Road, Huangpu District, Shanghai, PRC to consider and, if thought fit, pass the resolutions set out in the notice of the EGM. The notice convening the EGM is set out on pages EGM-1 to EGM-5 of this circular and is available on the websites of the Company (www.alebund.com) and the Stock Exchange (www.hkexnews.hk).

IV. CLOSURE OF REGISTER OF MEMBERS

The record date for the purpose of ascertaining the eligibility of the holders of H Shares and Unlisted Shares to attend and vote at the EGM is on Friday, August 14, 2026. In order to ascertain holders of H Shares who are entitled to attend the EGM, the register of members of holders of H Shares will be closed from Tuesday, August 11, 2026 to Friday, August 14, 2026 (both days inclusive). Holders of H Shares who intend to attend the EGM are required to lodge all completed transfer documents accompanied by the relevant share certificates with the Company's H Share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong on

LETTER FROM THE BOARD

or before 4:30 p.m. on Monday, August 10, 2026 for registration. Holders of Unlisted Shares who intend to attend the EGM are required to lodge all completed transfer documents accompanied by the relevant share certificates at the office of the Company, at Meeting Room 303, 1206, Hong Kong Plaza South Building, No.283, Middle Huaihai Road, Huangpu District, Shanghai, PRC on or before 10:00 a.m. on Friday, August 14, 2026 for registration.

V. PROXY ARRANGEMENT

The form of proxy for use at the EGM is enclosed with this circular and is also available on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.aledund.com).

Shareholders who intend to appoint a proxy to attend the EGM are required to complete and return the form of proxy to (i) the Company's H Share registrar, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for holders of H Shares); or (ii) the office of the Company, at Meeting Room 303, 1206, Hong Kong Plaza South Building, No.283, Middle Huaihai Road, Huangpu District, Shanghai, PRC (for holders of Unlisted Shares), in accordance with the instructions printed thereon as soon as possible and in any event not less than 24 hours before the time appointed for holding the EGM or any adjournment thereof, i.e. not later than 10:00 a.m. on Thursday, August 13, 2026, in order to be valid. Completion and return of the form of proxy will not preclude you from attending and voting in person at the EGM or any adjournment thereof should you so wish, in which case the returned form of proxy shall be deemed to be revoked.

VI. VOTING BY POLL

Pursuant to Rule 13.39(4) of the Listing Rules, all resolutions set out in the notice of the EGM will be voted on by poll. The poll results will be announced by the Company after the EGM in the manner prescribed under Rule 13.39(5) of the Listing Rules.

To the best knowledge, information and belief of the Directors having made all reasonable enquiries, no Shareholder has a material interest in the resolutions to be proposed at the EGM and no Shareholder is required to abstain from voting on any of the resolutions at the EGM.

Treasury Shares, if any, registered in the name of the Company shall have no voting rights at general meetings of the Company. For the avoidance of doubt, Treasury Shares, if any, pending withdrawal from and/or transfer through CCASS shall not bear any voting rights at general meetings of the Company.

LETTER FROM THE BOARD

VII. RESPONSIBILITY STATEMENT

This circular, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that to the best of their knowledge and belief the information contained in this circular is accurate and complete in all material respects and not misleading or deceptive, and there are no other matters the omission of which would make any statement herein or this circular misleading.

VIII. RECOMMENDATIONS

The Directors consider that the proposed resolutions set out in the notice of the EGM and the other matters contained in the notice of EGM, are in the interests of the Company and the Shareholders as a whole. Accordingly, the Directors recommend Shareholders to vote in favour of the relevant resolutions to be proposed at the EGM.

By order of the Board
Alebund Pharmaceuticals (Jiangsu) Limited
Dr. Gavin Guoyao Xia
Chairman of the Board, executive Director and
Chief Executive Officer

This appendix serves as the explanatory statement required to be sent to the Shareholders under the Listing Rules in connection with the proposed Repurchase Mandate. It contains information reasonably necessary to enable the Shareholders to make an informed decision on whether to vote for or against the resolution approving the Repurchase Mandate.

1. Share capital

As at the Latest Practicable Date, the total number of issued Shares was 339,852,231, comprising 227,122,189 H Shares and 112,730,042 Unlisted Shares. The Company did not hold any Treasury Shares as at the Latest Practicable Date. Pursuant to the announcement on the full exercise of the Over-allotment Option dated July 24, 2026, the Over-allotment Option has been fully exercised and an aggregate of additional 8,513,300 H Shares will be issued and listed on the Stock Exchange on July 29, 2026. The total number of issued Shares following the exercise of the Over-allotment Option will then be 348,365,531, comprising 235,635,489 H Shares and 112,730,042 Unlisted Shares.

Subject to the passing of the resolution approving the Repurchase Mandate and assuming that no further H Shares (other than any H Shares allotted and issued pursuant to the exercise of the Over-allotment Option) are issued or repurchased and no Treasury Shares are held before the passing of the relevant resolution at the EGM, the Company would be allowed under the Repurchase Mandate to repurchase up to 23,563,548 H Shares, representing 10% of the total number of H Shares in issue (taking into account the exercise of Over-allotment Option but excluding Treasury Shares, if any) as at the date of passing the relevant resolution at the EGM.

2. Reasons for repurchase

The Directors believe that the Repurchase Mandate is in the interests of the Company and the Shareholders as a whole. Repurchases of H Shares may, depending on market conditions and funding arrangements at the relevant time, enhance the net asset value and/or earnings per Share, improve capital efficiency and provide the Company with additional flexibility in capital management.

3. Funding of repurchases

Repurchases of H Shares pursuant to the Repurchase Mandate will be funded from funds legally available for such purpose in accordance with the Articles of Association, the laws and regulations of the PRC, the Listing Rules and other applicable laws and regulations. As H Shares are traded on the Stock Exchange in Hong Kong dollars, any repurchase of H Shares may be subject to applicable foreign exchange, regulatory filing or approval requirements in the PRC, including requirements of the State Administration of Foreign Exchange and other relevant authorities, if applicable.

4. Impact on working capital or gearing position

On the basis of the financial position of the Group as disclosed in the latest published financial information of the Company and taking into account the current working capital position of the Group, the Directors consider that there might be a material adverse impact on the working capital or gearing position of the Group if the Repurchase Mandate were to be exercised in full at any time during the proposed repurchase period. However, the Directors do not intend to exercise the Repurchase Mandate to such extent as would, in the circumstances, have a material adverse effect on the working capital requirements or gearing level of the Group which in the opinion of the Directors are from time to time appropriate for the Group.

5. General

The Directors will exercise the Repurchase Mandate in accordance with the Listing Rules, the Articles of Association and all applicable laws and regulations. The Directors will not exercise the Repurchase Mandate to an extent that would result in the number of H Shares held by the public falling below the prescribed minimum public float requirement under the Listing Rules.

If the Company repurchases H Shares pursuant to the Repurchase Mandate, the Company may cancel the repurchased H Shares and reduce its registered capital, and/or hold the repurchased H Shares as Treasury Shares, subject to the Listing Rules, applicable PRC laws and regulations, market conditions and the Company's capital management needs at the relevant time. If any repurchased H Shares are held as Treasury Shares, the Company will ensure that Treasury Shares are appropriately identified and segregated and that the voting rights attaching to such Treasury Shares are suspended in accordance with the Listing Rules and applicable laws and regulations.

To the best knowledge of the Directors, there is nothing unusual in this explanatory statement and the proposed Repurchase Mandate.

6. Directors, their close associates and core connected persons

None of the Directors nor, to the best of their knowledge having made all reasonable enquiries, any of their close associates, has any present intention to sell any H Shares to the Company if the Repurchase Mandate is approved by the Shareholders.

No core connected person of the Company has notified the Company that he/she/it has a present intention to sell any H Shares to the Company, or has undertaken not to do so, if the Repurchase Mandate is approved by the Shareholders.

The Company will not knowingly repurchase H Shares from any core connected person of the Company.

7. Takeovers Code

If, as a result of a repurchase of H Shares by the Company, a Shareholder's proportionate interest in the voting rights of the Company increases, such increase will be treated as an acquisition of voting rights for the purposes of the Takeovers Code. Accordingly, a Shareholder, or a group of Shareholders acting in concert, could obtain or consolidate control of the Company and become obliged to make a mandatory offer under Rule 26 of the Takeovers Code as a result of any such increase.

To the best knowledge of the Directors, the Directors are not aware of any consequence under the Takeovers Code that would arise as a result of any repurchase of H Shares pursuant to the Repurchase Mandate. The Directors have no present intention to exercise the Repurchase Mandate to such an extent as would give rise to an obligation to make a mandatory offer under the Takeovers Code or result in the Company failing to comply with the public float requirements under the Listing Rules.

8. Share repurchases made by the Company

The Company has not repurchased any H Shares on the Stock Exchange or otherwise during the period from June 29, 2026 (the date of listing of the H Shares on the Stock Exchange, the "**Listing Date**") to the Latest Practicable Date.

9. H Share prices

The highest and lowest prices at which the H Shares were traded on the Stock Exchange during the period from the Listing Date up to the Latest Practicable Date are as follows:

Month	Highest traded price per H Share (HK\$)	Lowest traded price per H Share (HK\$)
June 2026 (from the Listing Date)	46.82	40.50
July 2026 (up to the Latest Practicable Date)	39.04	22.72

NOTICE OF EXTRAORDINARY GENERAL MEETING



Alebund Pharmaceuticals (Jiangsu) Limited **禮邦醫藥(江蘇)股份有限公司**

(A joint stock company incorporated in the People's Republic of China with limited liability)
(Stock Code: 09637)

NOTICE OF EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that an extraordinary general meeting (the “EGM”) of Alebund Pharmaceuticals (Jiangsu) Limited (the “Company”) will be held at 10:00 a.m. on Friday, August 14, 2026 at Meeting Room 303, 1206, Hong Kong Plaza South Building, No.283, Middle Huaihai Road, Huangpu District, Shanghai, PRC, or any adjournment thereof, for the purpose of considering and, if thought fit, passing with or without amendments, the following resolutions of the Company. Unless otherwise indicated, capitalised terms used in this notice shall have the same meanings as those defined in the circular of the Company dated July 24, 2026.

ORDINARY RESOLUTION

1. To consider and approve the appointment of Ernst & Young as the auditor of the Company for a term commencing from the date of passing of this resolution until the conclusion of the next annual general meeting of the Company, and to authorise the Board to fix its remuneration.

SPECIAL RESOLUTIONS

2. To consider and approve the granting of a general mandate to the Board to exercise the power of the Company to allot, issue and/or deal with additional Shares and/or sell or transfer Treasury Shares of the Company:

“THAT:

- (a) subject to paragraphs (c) and (d) below and in accordance with the Listing Rules, the Company Law of the PRC, other applicable laws and regulations and the Articles of Association, a general and unconditional mandate be and is hereby granted to the Board during the Relevant Period (as defined below) to exercise, once or more, all powers of the Company to allot, issue and/or deal with additional Shares and/or sell or transfer Treasury Shares of the Company, if any, and to make or grant offers, agreements and options which would or might require the exercise of such powers;

NOTICE OF EXTRAORDINARY GENERAL MEETING

- (b) the mandate under paragraph (a) above shall authorise the Board during the Relevant Period to make or grant offers, agreements and options which would or might require Shares to be allotted, issued and/or dealt with, or Treasury Shares to be sold or transferred, after the end of the Relevant Period;
- (c) the aggregate number of Shares allotted, issued and/or dealt with, and Treasury Shares sold or transferred, by the Board pursuant to the mandate under paragraph (a) above shall not exceed 20% of the total number of Shares in issue (excluding Treasury Shares, if any) as at the date of passing of this resolution, except for Shares which may be allotted, issued or dealt with pursuant to conversion of capital reserve into capital in accordance with the Company Law of the PRC and the Articles of Association;
- (d) the Board shall exercise the mandate under paragraph (a) above in compliance with the Listing Rules, the Company Law of the PRC, other applicable PRC laws and regulations and, where applicable, the requirements and approvals of the Stock Exchange, the China Securities Regulatory Commission and other relevant regulatory authorities;
- (e) for the purpose of this resolution, “Relevant Period” means the period from the date of passing of this resolution until whichever is the earliest of: (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required to be held under the Articles of Association or applicable laws and regulations; or (iii) the date on which the powers granted under this resolution are revoked or varied by a special resolution of the Shareholders in general meeting;
- (f) subject to the relevant approvals of the relevant authorities (if required) and the exercise of the powers granted under paragraph (a) above in accordance with applicable laws and regulations, the Board be and is hereby authorised to increase the registered capital of the Company to reflect the number of Shares allotted and issued upon the exercise of the powers granted under paragraph (a) above, provided that the registered capital of the Company shall not exceed 120% of the registered capital of the Company as at the date of passing of this resolution; and
- (g) the Board be and is hereby authorised to make such amendments to the Articles of Association as it considers appropriate and necessary to reflect any change in the share capital structure of the Company arising from the exercise of the powers granted under paragraph (a) above, and to handle related approval, registration and filing procedures.”

NOTICE OF EXTRAORDINARY GENERAL MEETING

3. To consider and approve the granting of a general mandate to the Board to repurchase H Shares:

“THAT:

- (a) subject to paragraphs (b) and (c) below and in accordance with the Listing Rules, the Company Law of the PRC, other applicable laws and regulations and the Articles of Association, a general mandate be and is hereby granted to the Board during the Repurchase Mandate Period (as defined below) to exercise all powers of the Company to repurchase H Shares on the Stock Exchange on such terms and conditions as the Board may determine;
- (b) the total number of H Shares which may be repurchased by the Company pursuant to the mandate under paragraph (a) above shall not exceed 10% of the total number of H Shares in issue (excluding Treasury Shares, if any) as at the date of passing of this resolution;
- (c) the Board shall exercise the mandate under paragraph (a) above in compliance with the Listing Rules, the Company Law of the PRC, other applicable PRC laws and regulations and, where applicable, the requirements and approvals of the Stock Exchange, the Securities and Futures Commission of Hong Kong, the China Securities Regulatory Commission and other relevant regulatory authorities;
- (d) the Board be and is hereby authorised to formulate, implement, suspend or terminate specific plans for the repurchase of H Shares, including but not limited to determining the timing, price and number of H Shares to be repurchased;
- (e) subject to the Listing Rules and applicable laws and regulations, the Board be and is hereby authorised to cancel the H Shares repurchased and reduce the registered capital of the Company, make corresponding amendments to the Articles of Association, notify the creditors of the Company, publish announcements, handle statutory registrations and filings, and/or hold the repurchased H Shares as Treasury Shares;
- (f) the Board be and is hereby authorised to handle all other matters in connection with the repurchase of H Shares, except for matters which must be exercised by the Shareholders in general meeting under applicable laws, regulations, the Listing Rules or the Articles of Association; and
- (g) for the purpose of this resolution, “Repurchase Mandate Period” means the period from the date of passing of this resolution until the earliest of: (i) the conclusion of the next annual general meeting of the Company; (ii) the expiration of the period within which the next annual general meeting of the Company is required to be held

NOTICE OF EXTRAORDINARY GENERAL MEETING

under the Articles of Association or applicable laws and regulations; or (iii) the date on which the mandate granted under this resolution is revoked or varied by a special resolution of the Shareholders in general meeting.”

Details of the above resolutions proposed at the EGM are contained in the circular of the Company dated July 24, 2026, which is available on the websites of the Stock Exchange (www.hkexnews.hk) and the Company (www.alebund.com).

By order of the Board
Alebund Pharmaceuticals (Jiangsu) Limited
Dr. Gavin Guoyao Xia
*Chairman of the Board, executive Director and
Chief Executive Officer*

Hong Kong, Friday, July 24, 2026

As at the date of this notice, the Board comprises: Dr. Gavin Guoyao Xia, Jin Tian, M.D., Ms. Wang Yun and Dr. Zhang Huading as executive Directors; Dr. Lu An as non-executive Director; and Dr. Xu Runhong, Dr. Zhui Chen and Mr. Leung Chi Wai as independent non-executive Directors.

Notes:

1. Resolution to be submitted at the EGM shall be voted on by poll.
2. The record date for the purpose of ascertaining the eligibility of the holders of H Shares and Unlisted Shares to attend and vote at the EGM is on Friday, August 14, 2026. In order to ascertain holders of H Shares who are entitled to attend the EGM, the register of members of holders of H Shares will be closed from Tuesday, August 11, 2026 to Friday, August 14, 2026 (both days inclusive). Holders of H Shares who intend to attend the EGM are required to lodge all completed transfer documents accompanied by the relevant share certificates with the Company's H Share registrar, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong on or before 4:30 p.m. on Monday, August 10, 2026 for registration. Holders of Unlisted Shares who intend to attend the EGM are required to lodge all completed transfer documents accompanied by the relevant share certificates at the office of the Company, at Meeting Room 303, 1206, Hong Kong Plaza South Building, No.283, Middle Huaihai Road, Huangpu District, Shanghai, PRC on or before 10:00 a.m. on Friday, August 14, 2026 for registration.
3. Shareholders who are entitled to attend and vote at the EGM may appoint one or more proxies to attend and vote on their behalf. A proxy need not be a Shareholder. If more than one proxy is appointed, the number and class of Shares in respect of which each such proxy is so appointed shall be specified in the appointment of the proxy.
4. The form of proxy must be signed by the Shareholder or by an authorised person appointed by the Shareholder in writing. If the Shareholder is a legal person, it must be stamped with the seal of the legal person or signed by a director or duly authorised attorney. If the form is signed by an attorney of the Shareholder, the power of attorney authorising that attorney to sign or other authorisation document must be notarised.

NOTICE OF EXTRAORDINARY GENERAL MEETING

5. In order to be valid, the form of proxy, and if the form of proxy is signed by a person under a power of attorney or other authorisation document on behalf of the appointor, a notarially certified copy of that power of attorney or other authorisation document, must be deposited with (i) the H Share registrar of the Company, Computershare Hong Kong Investor Services Limited, at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for holders of H Shares); or (ii) the office of the Company, at Meeting Room 303, 1206, Hong Kong Plaza South Building, No.283, Middle Huaihai Road, Huangpu District, Shanghai, PRC (for holders of Unlisted Shares), not less than 24 hours before the time appointed for holding the EGM or any adjournment thereof.

In case of joint holders of any Shares, any one of the joint holders can vote on such Shares at the EGM in person or by proxy as if he/she is the only holder entitled to vote. If more than one joint holders attend the EGM in person or by proxy, only the vote of the person whose name appears first in the register of members of the Company relating to such Shares will be accepted as the sole and exclusive vote of the joint holders.

Completion and return of the form of proxy will not preclude a Shareholder from attending and voting in person at the EGM or any adjournment thereof should he/she/it so wish. In this case, the power of attorney will be deemed to have been revoked.

6. Shareholders and their proxies are required to produce identity proof when attending the EGM (and any adjournment thereof).
7. The EGM is expected to last for no more than half a day. Shareholders or their proxies attending the EGM are responsible for their own transportation and accommodation expenses.
8. All times refer to Hong Kong local time, except as otherwise stated.